Capricor Therapeutics Faces Class Action Lawsuit with Deadline Approaching in 2026
In a significant development for investors in Capricor Therapeutics, Inc., a class action securities lawsuit has been initiated, raising concerns regarding the company's transparency and governance practices. This notice, issued by Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., aims to inform affected investors about their rights and the impending deadlines associated with the legal proceedings.
The lawsuit has been filed on behalf of investors who bought or acquired Capricor shares during a specified period from December 17, 2025, to July 26, 2026. This class action is pending before the United States District Court for the Southern District of California. Investors are urged to act swiftly, as the deadline to file an application to be appointed as lead plaintiff is September 28, 2026.
As outlined in the complaint, Capricor’s executives are accused of failing to disclose crucial information while violating federal securities laws. The allegations arise from a series of events culminating in a dramatic drop in stock value following an unfavorable announcement from the U.S. Food and Drug Administration (FDA).
On July 27, 2026, prior to market opening, the FDA released briefing documents regarding the company’s lead product candidate, Deramiocel. The FDA’s review highlighted major discrepancies, noting that Capricor had deviated from its pre-specified statistical analysis plan. The FDA raised concerns that critical alterations to the analysis undermined the scientific validity and accuracy of their findings.
According to the FDA, the final version of the statistical analysis plan was only completed just one day before the unblinding of the data, suggesting a lack of due diligence and transparency on Capricor’s part. These findings cast significant doubt on the drug’s effectiveness and resulted in a staggering decline of Capricor's stock price, plummeting to $7.00 per share after shedding $12.70, or 64% of its value.
For individuals who invested in Capricor Therapeutics and witnessed a financial loss during the outlined timeframe, it is crucial to consider joining the class action to seek potential recovery of losses incurred. Interested parties can reach out directly to KSF Managing Partner Lewis Kahn through their toll-free number or via email to discuss their case and rights as investors.
This legal action not only illuminates existing issues within corporate governance at Capricor Therapeutics but also serves as a reminder of the volatility associated with investing in biotechnology firms. Investors are encouraged to remain vigilant about the information surrounding their investments and the governing processes of the companies in which they choose to invest.
Kahn Swick & Foti, LLC has garnered recognition as a leading securities litigation law firm. With extensive experience in advocating for investors, KSF has successfully managed a range of cases involving corporate fraud and mismanagement. Their portfolio includes representing both institutional and retail investors, ensuring that those harmed by corporate misconduct have access to justice.
This case, titled Nkamga v. Capricor Therapeutics, Inc., et al., continues to develop as more evidence unfolds regarding the company's operational integrity. Capricor investors are urged to follow up promptly to safeguard their rights and interests in light of this ongoing legal matter.
Overview of the Legal Action
The lawsuit has been filed on behalf of investors who bought or acquired Capricor shares during a specified period from December 17, 2025, to July 26, 2026. This class action is pending before the United States District Court for the Southern District of California. Investors are urged to act swiftly, as the deadline to file an application to be appointed as lead plaintiff is September 28, 2026.
As outlined in the complaint, Capricor’s executives are accused of failing to disclose crucial information while violating federal securities laws. The allegations arise from a series of events culminating in a dramatic drop in stock value following an unfavorable announcement from the U.S. Food and Drug Administration (FDA).
Key Events Leading to the Lawsuit
On July 27, 2026, prior to market opening, the FDA released briefing documents regarding the company’s lead product candidate, Deramiocel. The FDA’s review highlighted major discrepancies, noting that Capricor had deviated from its pre-specified statistical analysis plan. The FDA raised concerns that critical alterations to the analysis undermined the scientific validity and accuracy of their findings.
According to the FDA, the final version of the statistical analysis plan was only completed just one day before the unblinding of the data, suggesting a lack of due diligence and transparency on Capricor’s part. These findings cast significant doubt on the drug’s effectiveness and resulted in a staggering decline of Capricor's stock price, plummeting to $7.00 per share after shedding $12.70, or 64% of its value.
What Investors Should Know
For individuals who invested in Capricor Therapeutics and witnessed a financial loss during the outlined timeframe, it is crucial to consider joining the class action to seek potential recovery of losses incurred. Interested parties can reach out directly to KSF Managing Partner Lewis Kahn through their toll-free number or via email to discuss their case and rights as investors.
This legal action not only illuminates existing issues within corporate governance at Capricor Therapeutics but also serves as a reminder of the volatility associated with investing in biotechnology firms. Investors are encouraged to remain vigilant about the information surrounding their investments and the governing processes of the companies in which they choose to invest.
About Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC has garnered recognition as a leading securities litigation law firm. With extensive experience in advocating for investors, KSF has successfully managed a range of cases involving corporate fraud and mismanagement. Their portfolio includes representing both institutional and retail investors, ensuring that those harmed by corporate misconduct have access to justice.
This case, titled Nkamga v. Capricor Therapeutics, Inc., et al., continues to develop as more evidence unfolds regarding the company's operational integrity. Capricor investors are urged to follow up promptly to safeguard their rights and interests in light of this ongoing legal matter.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.